Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WatersMEX:WAT 91 14-Day RSI is 89.66 as of Jul. 15, 2026. GuruFocus rates MEX:WAT with a GF Score™ of 91/100 and a GF Value™ of MXN7,547.00 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Waters ranks worse than 73.73% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-15), Waters's 14-Day RSI is 89.66.
The industry rank for Waters's 14-Day RSI or its related term are showing as below:
MEX:WAT's 14-Day RSI is ranked worse than 73.73% of 217
companies
in the Medical Diagnostics & Research industry
Industry Median: 48.56
vs MEX:WAT: 89.66
Waters (MEX:WAT) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Waters 14-Day RSI Related Terms
MEX:WAT vs NTRA, A, IQV: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, Waters's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Waters 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Waters's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Waters's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Waters (MEX:WAT) has a 14-Day RSI of 89.66 as of Jul. 15, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Waters and its competitors. According to the industry distribution chart, Waters ranks #160 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 73.7%.
Is Waters' 14-Day RSI too high?
Waters' current 14-Day RSI is 89.66. The Medical Diagnostics & Research industry median 14-Day RSI is 48.56. Waters' value of 89.66 is 84.6% above this industry median. Based on the distribution chart, Waters ranks #160 out of 217 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Waters has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Waters' 14-Day RSI compare to NTRA and A?
According to the Medical Diagnostics & Research industry distribution chart, Waters ranks #160 out of 217 companies for 14-Day RSI. This places Waters in the lower half of its industry. The industry median 14-Day RSI is 48.56. Waters' value of 89.66 is 84.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 48.56, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Waters's current 14-Day RSI of 89.66 is 84.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Waters and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 48.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Waters's current 14-Day RSI is 89.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Waters stock overvalued right now?
Based on GuruFocus' analysis, Waters (MEX:WAT) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN7,547.00, compared to a current price of MXN6,660.45 — trading 11.7% below its estimated fair value. The current 14-Day RSI is 89.66 and 84.6% above the Medical Diagnostics & Research industry median of 48.56. Waters' overall GF Score™ is 91/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Waters (MEX:WAT), the current 14-Day RSI is 89.66 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Waters (MEX:WAT) Overvalued in 2026?
Based on GuruFocus' analysis, Waters stock appears to be undervalued.
The current stock price of MXN6,660.45 is trading 11.7% below its estimated GF Value™ of MXN7,547.00.
GuruFocus considers Waters to be Modestly Undervalued.
Key valuation signals for MEX:WAT:
14-Day RSI: 89.66
GF Value™: MXN7,547.00 vs. price of MXN6,660.45 (11.7% below fair value)
Industry Position: 84.6% above the Medical Diagnostics & Research median (#160 of 217)
No single metric tells the full story. See the MEX:WAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.
91GF Score
Get the complete analysis for MEX:WAT
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:WAT has been successfully added to your 
